Manufacturing

Latest News


Review of SUT Adoption in Biopharma Manufacturing

The evolution of therapeutic modalities drives the adoption of single-use technologies.

Review of SUT Adoption in Biopharma Manufacturing

Why Are Pharmaceutical Companies Reluctant to Adopt Cloud Technologies?

Despite its understandable hesitancy, the pharma industry is facing a need for more widespread adoption of cloud-based solutions.

Why Are Pharmaceutical Companies Reluctant to Adopt Cloud Technologies?

Automating the Future of Fill/Finish

Given the criticality of fill/finish processes, it is clear that automation is the next technological step.

 Automating the Future of Fill/Finish

i1-675714-1408633098470.jpg

Pharmaceutical Technology Europe

We decided to dedicate this month's issue of PTE to a topic that affects all of our readers; the threat of counterfeit medicines.

ePT--the Electronic Newsletter of Pharmaceutical Technology

European pharmaceutical companies are outdoing their US counterparts when it comes to making medicines available to developing countries, according to the Access to Medicine Index, which analyzes and ranks the access to medicine efforts of the world's largest pharma companies.

ePT--the Electronic Newsletter of Pharmaceutical Technology

About one month after the announcement of McNeil Consumer Healthcare's recall of children's liquid pain and allergy medications , the US Food and Drug Administration testified before the US House Committee on Oversight and Government Reform about the issue.

Europe moves to place excipient GMP and GDP standards on the same level as active pharmaceutical ingredients.

Pharmaceutical Technology Europe

A laboratory information system (LIMS) is a key tool in facilitating communication between a pharmaceutical company and its outsourcing partners; however, most LIMS require extensive customisation before they can be used in the pharmaceutical industry.

Pharmaceutical Technology Europe

An effective quality management system will identify the root cause of non-conformances and put measures in place to ensure that they do not recur, but is the pharmaceutical industry choosing the right methods to make sure this happens?